A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.
about
Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus HemagglutininThe notorious R.N.A. in the spotlight - drug or target for the treatment of diseaseDistinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.Developments in cancer vaccines for hepatocellular carcinoma.Current state in the development of candidate therapeutic HPV vaccinesImmunological effects of a novel RNA-based adjuvant in liver cancer patients.Mechanism of action of mRNA-based vaccines.Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses.Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.Use of adjuvants for immunotherapy.A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects.Cancer vaccines for hepatocellular carcinoma: future directions.Computational Prediction of the Immunomodulatory Potential of RNA Sequences.Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy.Cationic domains in particle-forming and assembly-deficient HBV core antigens capture mammalian RNA that stimulates Th1-biased antibody responses by DNA vaccination
P2860
Q30380290-E15045AF-33C9-4DFB-9FD9-54A5316A2A9DQ33739733-5AA817D3-738C-40BF-9109-C78CF1A984D7Q37559326-DEBB2343-B056-46CD-8468-3DF16B69024FQ38533017-D2BDFF3F-D26F-4A23-A597-C8459A508D3AQ38743922-909C653E-551D-4BF3-8C37-609B67B45214Q39198568-DD30C1D2-5B27-41D1-B2BE-2B7385431F56Q39431058-B2B8A809-93E3-4F52-BC5A-9E0F2DF9FC6BQ39432584-340C7B7E-F76D-4A02-845E-EB4FBC36FB4BQ39829133-B36A9B10-64F7-4468-AA1C-B0A45C877121Q40163884-EF8F10E4-43A9-470F-808B-0D7F3FBE67B9Q40375946-C773AEFB-5AC4-4729-A21E-3A1C72F33C6BQ44211246-23B58A6D-B088-4978-B0CC-300EDB193B07Q45946589-52F5DD87-6AA1-49AD-A6D4-88338900A3FDQ50115667-F421B5E2-F4AC-4FD6-8463-26FF6D245666Q55163909-C0F99D2A-ABF2-4CCE-8361-DFD73B8B49CFQ57050439-3D4A9036-D6E1-4151-91CF-ACBA27769350
P2860
A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A novel RNA-based adjuvant com ...... th a favorable safety profile.
@en
type
label
A novel RNA-based adjuvant com ...... th a favorable safety profile.
@en
prefLabel
A novel RNA-based adjuvant com ...... th a favorable safety profile.
@en
P2093
P2860
P356
P1476
A novel RNA-based adjuvant com ...... th a favorable safety profile.
@en
P2093
Aleksandra Kowalczyk
Birgit Scheel
Edith Jasny
Jochen Probst
Johannes Lutz
Karl-Josef Kallen
Mariola Fotin-Mleczek
Patrick Baumhof
Regina Heidenreich
Söhnke Voss
P2860
P304
P356
10.1002/IJC.29402
P577
2015-01-08T00:00:00Z